Next 10 |
home / stock / tcrx / tcrx articles
WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on...
WALTHAM, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on...
WALTHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on...
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday. Shares of Worthington Steel, Inc. (NYSE: WS) rose sharply dur...
Presented updated data from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies at the Tandem Meetings of ASTCT an...
TScan's abstract selected by the Tandem Meetings to receive a Best Abstracts Award Company to discuss the potential implications of initial d...
Presentation to include additional results from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies WALTHAM, Mass....
Reported positive initial data from Phase 1 heme program at the 65th American Society of Hematology (ASH) Annual Meeting Clearance of INDs for fou...
WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on ...
News, Short Squeeze, Breakout and More Instantly...
TScan Therapeutics Inc. Company Name:
TCRX Stock Symbol:
NYSE Market:
WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on...
WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the accept...
WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the underw...